An interventional study of Hydrogen-rich water consumption and Drinking water consumption in Dysmenorrhea Primary, sponsored by Menekşe Nazlı AKER. Not yet recruiting. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Menekşe Nazlı AKER · Not applicable, Interventional, and Supportive care
The study will include hydrogen-rich water and control groups. Young women with severe primary dysmenorrhea will be recruited from Ankara University. Eligible women will be informed about the study, and written informed consent will be obtained. Participants will be assigned to the study groups using block randomization.
430 studies on the registry are indexed under Dysmenorrhea; 107 are open to participants now.
This study's planned enrollment of 48 is below the median of 62 across 363 interventional studies indexed under Dysmenorrhea.
Browse Dysmenorrhea studies →Menekşe Nazlı AKER is the lead sponsor of 7 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Hydrogen-rich water consumption
Other: Drinking water consumption
Participants will begin consuming hydrogen-rich water after menstruation ends in the baseline cycle and continue daily for three months. They will be asked to drink 1,500-2,000 mL (1.5-2.0 L) per day. Adherence will be monitored using a daily water intake log.
Participants will begin consuming water after menstruation ends in the baseline cycle and continue daily for three months. They will be asked to drink 1,500-2,000 mL (1.5-2.0 L) per day. Adherence will be monitored using a daily water intake log.
WaLIDD Score
The WaLIDD Score was developed by Teherán et al. The scale, which underwent a Turkish validity and reliability study by Fidancı et al. in 2025, is a four-item assessment tool. Each item is scored between 0 and 3 points, yielding a total score range of 0-12. The scale evaluates four dimensions: work affected (the impact of pain on daily functioning), localization of pain (the anatomical distribution of pain), intensity of pain (a subjective assessment based on the Wong-Baker Faces Pain Scale), and duration of pain (the number of painful days during menstruation). A total score of "0" indicates no dysmenorrhea, scores of "1-4" indicate mild dysmenorrhea, scores of "5-7" indicate moderate dysmenorrhea, and scores of "8-12" indicate severe dysmenorrhea.
Time frame: Baseline (days 5-7 of the first menstrual cycle) and follow-up (days 5-7 of the third menstrual cycle)
Menstrual Symptom Questionnaire
The Menstrual Symptom Questionnaire was developed by Chesney and Tasto. The scale, which underwent a Turkish validity and reliability study by Güvenç in 2014, consists of twenty-two items rated on a five-point Likert-type format. Participants rate their menstrual symptoms on a scale from 1 to 5, where 1 indicates "never" and 5 indicates "always." The total score of the Menstrual Symptom Questionnaire is obtained as the mean of the sum of all items. In the original version of the scale, there are three subdimensions: negative affect/somatic complaints, menstrual pain, and abdominal pain.
Time frame: Baseline (days 5-7 of the first menstrual cycle) and follow-up (days 5-7 of the third menstrual cycle)
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Feb 2027, 4 months later.
Of 178 non-industry interventional studies with no phase under Dysmenorrhea, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's planned 4 months is below that.
Counting every sponsor, half of 188 studies reached it within 8 months; a quarter within 3 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Menekşe Nazlı AKER